Intrigue: Phase III study of ripretinib vs sunitinib in advanced gastrointestinal stromal tumor (GIST) after imatinib therapy

Assess the efficacy of ripretinib versus sunitinib as measured by PFS by BICR using mRECIST v1.1 in patients with advanced GIST who have progressed on or were intolerant to first-line therapy with imatinib.

Assess the ORR by BICR using mRECIST v1.1 and OS of ripretinib in patients with advanced GIST who have progressed on or were intolerant to first-line therapy with imatinib.

PFS: Progression-free survival

OS: Overall survival

BICR: Blinded independent central review; GIST: Gastrointestinal stromal tumor; mRECIST v1.1: Modified Response Evaluation Criteria in Solid Tumors version 1.1; ORR: Objective response rate;